Compare PRTA & DC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTA | DC |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | Ireland | United States |
| Employees | N/A | 41 |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.7M | 567.9M |
| IPO Year | 2013 | N/A |
| Metric | PRTA | DC |
|---|---|---|
| Price | $9.75 | $4.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $19.00 | $9.48 |
| AVG Volume (30 Days) | 596.8K | ★ 2.0M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $814,000.00 | N/A |
| Revenue This Year | $1,111.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.42 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.18 | $3.60 |
| 52 Week High | $11.80 | $7.25 |
| Indicator | PRTA | DC |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 39.02 |
| Support Level | $8.91 | $3.85 |
| Resistance Level | $10.34 | $4.43 |
| Average True Range (ATR) | 0.48 | 0.24 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 80.11 | 20.52 |
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Dakota Gold Corp is a gold exploration and development company focused on revitalizing the Homestake District in Lead, South Dakota. The company holds gold mineral properties surrounding the historic Homestake Mine and is advancing key projects, including the Richmond Hill Project.